@article{06b3a0c7833d40e48c7cf9e663682a12,
title = "Genetic analyses identify GSDMB associated with asthma severity, exacerbations, and antiviral pathways",
abstract = "Background: The Chr17q12-21.2 region is the strongest and most consistently associated region with asthma susceptibility. The functional genes or single nucleotide polymorphisms (SNPs) are not obvious due to linkage disequilibrium. Objectives: We sought to comprehensively investigate whole-genome sequence and RNA sequence from human bronchial epithelial cells to dissect functional genes/SNPs for asthma severity in the Severe Asthma Research Program. Methods: Expression quantitative trait loci analysis (n = 114), correlation analysis (n = 156) of gene expression and asthma phenotypes, and pathway analysis were performed in bronchial epithelial cells and replicated. Genetic association for asthma severity (426 severe vs 531 nonsevere asthma) and longitudinal asthma exacerbations (n = 273) was performed. Results: Multiple SNPs in gasdermin B (GSDMB) associated with asthma severity (odds ratio, >1.25) and longitudinal asthma exacerbations (P < .05). Expression quantitative trait loci analyses identified multiple SNPs associated with expression levels of post-GPI attachment to proteins 3, GSDMB, or gasdermin A (3.1 × 10−9 < P < 1.8 × 10−4). Higher expression levels of GSDMB correlated with asthma and greater number of exacerbations (P < .05). Expression levels of GSDMB correlated with genes involved in IFN signaling, MHC class I antigen presentation, and immune system pathways (false-discovery rate–adjusted P < .05). rs1031458 and rs3902920 in GSDMB colocalized with IFN regulatory factor binding sites and associated with GSDMB expression, asthma severity, and asthma exacerbations (P < .05). Conclusions: By using a unique set of gene expression data from lung cells obtained using bronchoscopy from comprehensively characterized subjects with asthma, we show that SNPs in GSDMB associated with asthma severity, exacerbations, and GSDMB expression levels. Furthermore, its expression levels correlated with asthma exacerbations and antiviral pathways. Thus, GSDMB is a functional gene for both asthma susceptibility and severity.",
keywords = "Antiviral pathways, GSDMA, GSDMB, PGAP3, RNAseq, asthma exacerbations, asthma severity, eQTL, genetics, whole-genome sequence",
author = "{NHLBI Severe Asthma Research Program (SARP)} and Xingnan Li and Christenson, {Stephanie A.} and Brian Modena and Huashi Li and Busse, {William W.} and Mario Castro and Denlinger, {Loren C.} and Erzurum, {Serpil C.} and Fahy, {John V.} and Benjamin Gaston and Hastie, {Annette T.} and Elliot Israel and Jarjour, {Nizar N.} and Levy, {Bruce D.} and Moore, {Wendy C.} and Woodruff, {Prescott G.} and Naftali Kaminski and Wenzel, {Sally E.} and Bleecker, {Eugene R.} and Meyers, {Deborah A.}",
note = "Funding Information: The Severe Asthma Research Program (SARP) cross-sectional cohort was supported by the National Institutes of Health (NIH; grant nos. HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, and HL091762). The SARP longitudinal cohort was funded by the National Heart, Lung, and Blood Institute (NHLBI; grant nos. U10 HL109172, HL109168, HL109152, HL109257, HL109146, HL109250, HL109164, and HL109086). Genetic studies for the SARP cross-sectional cohort were funded by the NIH (grant no. HL87665) and Go Grant (grant no. RC2HL101487). SARP whole-genome sequencing was supported by NHLBI Trans-Omics for Precision Medicine X01 grant.We acknowledge all investigators, staff, and participants in the SARP studies. TOPMed Acknowledgments: Molecular data for the TOPMed program were supported by the National Heart, Lung, and Blood Institute (NHLBI). Genome sequencing for ?NHLBI TOPMed: Severe Asthma Research Program? (phs001446) was performed at the New York Genome Center (HHSN268201500016C). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering, were provided by the TOPMed Informatics Research Center (grant no. 3R01HL-117626-02S1; contract no. HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (grant nos. R01HL-120393 and U01HL-120393; contract no. HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. Disclosure of potential conflict of interest: B. Modena reports grants from the National Heart, Lung, and Blood Institute (NHLBI) and personal fees from Sanofi, Regeneron, GlaxoSmithKline (GSK), Circassia, and AstraZeneca. W. W. Busse has received consulting fees from AstraZeneca, Genentech, Regeneron, Novartis, Sanofi, and GSK. M. Castro receives university grant funding from the National Institutes of Health (NIH), the American Lung Association, and Patient-Centered Outcomes Research Institute, receives pharmaceutical grant funding from AstraZeneca, Chiesi, Novartis, GSK, and Sanofi-Aventis, serves as a consultant for Genentech, Theravance, VIDA, Teva, and Sanofi-Aventis and also as a speaker for AstraZeneca, Genentech, GSK, Regeneron, Sanofi, and Teva, and receives royalties from Elsevier. L. C. Denlinger has active grant funding from the NHLBI and has consulted in the last 3 years with AstraZeneca. A. T. Hastie reports grants from the NIH and grant support from Genentech during the conduct of the study. B. D. Levy reports grants from the NHLBI and personal fees from AstraZeneca, Bayer, Gossamer Bio, Merck, Nocion Therapeutics, Pieris Pharmaceuticals, Teva Pharmaceuticals, SRA, and Sanofi. P. G. Woodruff reports personal fees from Sanofi, Glenmark Pharmaceuticals, Theravance, GSK, NGM Pharma, Amgen, and Genentech. S. E. Wenzel has consulted for AstraZeneca, Genentech, GSK, and Sanofi-Aventis in the last 3 years, in matters unrelated to the content of this manuscript, participated in multicenter clinical trial for AstraZeneca, GSK, Novartis, and Sanofi-Aventis in the last 3 years, unrelated to this manuscript, and received financial support for the last 2 years of SARP from an unrestricted grant from Boehringer Ingelheim. E. R. Bleecker has performed clinical trials through his employer, Wake Forest School of Medicine and University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech, Novartis, Regeneron, and Sanofi Genzyme, and has also served as a paid consultant for ALK-Abell?, AstraZeneca, MedImmune, GSK, Novartis, Regeneron, Sanofi Genzyme, and Teva, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: The Severe Asthma Research Program (SARP) cross-sectional cohort was supported by the National Institutes of Health ( NIH ; grant nos. HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665 , and HL091762 ). The SARP longitudinal cohort was funded by the National Heart, Lung, and Blood Institute ( NHLBI ; grant nos. U10 HL109172, HL109168, HL109152, HL109257, HL109146, HL109250, HL109164 , and HL109086 ). Genetic studies for the SARP cross-sectional cohort were funded by the NIH (grant no. HL87665 ) and Go Grant (grant no. RC2HL101487 ). SARP whole-genome sequencing was supported by NHLBI Trans-Omics for Precision Medicine X01 grant. Funding Information: TOPMed Acknowledgments: Molecular data for the TOPMed program were supported by the National Heart, Lung, and Blood Institute (NHLBI). Genome sequencing for “NHLBI TOPMed: Severe Asthma Research Program” (phs001446) was performed at the New York Genome Center (HHSN268201500016C). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering, were provided by the TOPMed Informatics Research Center (grant no. 3R01HL-117626-02S1; contract no. HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (grant nos. R01HL-120393 and U01HL-120393; contract no. HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. Publisher Copyright: {\textcopyright} 2020 American Academy of Allergy, Asthma & Immunology",
year = "2021",
month = mar,
doi = "10.1016/j.jaci.2020.07.030",
language = "English (US)",
volume = "147",
pages = "894--909",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",
}